Evercyte brings new extracellular vesicle research focus to ISEV Kyoto
Press Release | Evercyte GmbH
APRIL 10, 2019
Vienna, Austria: – Innovative biotech manufacturer Evercyte will be a prominent contributor to the Annual Meeting of the International Society of Extracellular Vesicles (ISEV 2019) in the ancient Japanese city of Kyoto.
Evercyte’s Chief Scientific Officer, Dr. Johannes Grillari, CSO, will present a lecture on the role of ‘Extracellular vesicles in ageing: from skin to bone’ on Day Three of the conference (Friday, April 26) during the Giovanni session, which he will also chair.
Dr. Grillari, a leading expert in cell and molecular biology, will also present a poster on ‘Tissue injury and repair’ during the P20 session on the same day between 15:30 and 16:30 hours.
This is a return by Evercyte to the ISEV conference that is being held in an Asian city for the first time.
“This is a high-level scientific event, attracting academics and scientists in pharmaceutical, chemical and cosmetic industries, along with researchers from academic institutions and CROs, providing an excellent platform for presenting Evercyte’s advanced solutions and services,” commented Dr. Grillari.
Evercyte Chief Technology Officer Dr. Regina Grillari, CTO, a world-recognized expert in cell biology and cell line development, will also attend the ISEV conference.
“We will be focusing on Evercyte´s new research focus on Extracellular Vesicles (EVs) and the portfolio of associated services,” said Regina Grillari.
“These include EV engineering, generating specific targeted and recombinant EVs, characterization and production of EVs, establishment of novel hosts for EVs, generating customer-tailored human telomerized cells by cell type and donor; gene editing for EV production and individualized cell line development of human cell lines and gene editing studies,” she explained.
About Evercyte GmbH
Evercyte GmbH, based in Vienna, manufactures a range of innovative cell-based products; telomerase (hTERT) immortalized or life span extended cells and differentiated cells from immortalized or normal stem cells.
Evercyte has also become a key player in the development of induced pluripotent stem (iPS) cells from human urine as a non-invasive source for generating cell material. The company also offers a range of cell-based assays, used in development of drug screening strategies and other applications. It also develops assays to individual specification to help customers reduce their time and spend on drug discovery and development.
Evercyte’s Pharmacocellomics™ is also improving the predictability of substance efficiencies and side effects in the general population by systematically establishing and commercializing relevant cell type specific model systems from donors of different genetic backgrounds.
Founded in 2011, the Vienna-based company successfully offers tools and the know-how necessary for the establishment of standardized high-throughput target identification and drug screening strategies, for toxicity studies, or for efficacy testing from statistically relevant numbers of donors. In addition, Evercyte now also focuses on using telomerized cells as cell factories. Further information at www.evercyte.com.
About ISEV 2019
The International Society for Extracellular Vesicles is the leading professional society for researchers and scientists involved in the study of microvesicles and exosomes.
With nearly 1,000 members, ISEV continues to be the leader in advancing the study of extracellular vesicles globally. Founded in 2012 in Sweden, ISEV is now headquartered in the USA.
Through its programs and services, ISEV provides essential training and research opportunities for those involved in exosome and microvesicle research.
The ISEV Annual Meeting draws nearly 1,000 attendees, including top researchers in the field discussing the latest in extracellular vesicles, exosomes, and microvesicles.
For the first time being held in Asia-Pacific region, ISEV 2019 is a five-day event opening 24 April at the Miyako Messe in Kyoto, Japan.
The event is organized by ISEV, with further information at: www.isev.org/page/ISEV2019.
Elisabeth Schraml, Project Management & Business Development, Evercyte GmbH
Tel: +43 699 10 709 401